Patents by Inventor Bradley Paul Sullivan

Bradley Paul Sullivan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and methods for the treatment of COVID-19
    Patent number: 11926642
    Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: March 12, 2024
    Assignee: Pfizer inc.
    Inventors: Robert Steven Kania, Padmavani Bezawada, Emma Louise Hawking, Rohit Jaini, Samir Kulkarni, Matthew Nathan O'Brien Laramy, Jonathan Richard Lillis, Suman Luthra, Dafydd Rhys Owen, Klimentina Dimitrova Pencheva, Anil Mahadeo Rane, Matthew Forrest Sammons, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst, Jamison Bryce Tuttle, Robert Louis Hoffman
  • Methods of Inhibiting SARS-CoV-2 Replication and Treating Corona Virus Disease 2019
    Publication number: 20230157998
    Abstract: The invention relates to methods of treating COVID-19 in a patient by administering therapeutically effective amounts of certain SARS-CoV-2 inhibitor compounds or pharmaceutical compositions containing them to a patient in need thereof.
    Type: Application
    Filed: March 3, 2021
    Publication date: May 25, 2023
    Applicant: Pfizer Inc.
    Inventors: Padmavani Bezawada, Benjamin Joseph Burke, Emma Louise Hawking, Robert Louis Hoffman, Robert Steven Kania, Jonathan Richard Lillis, Matthew Nathan O'Brien Laramy, Klimentina Dimitrova Pencheva, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst
  • Compounds and Methods for the Treatment of COVID-19
    Publication number: 20220017548
    Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.
    Type: Application
    Filed: July 1, 2021
    Publication date: January 20, 2022
    Applicant: Pfizer Inc.
    Inventors: Robert Steven Kania, Padmavani Bezawada, Emma Louise Hawking, Rohit Jaini, Samir Kulkarni, Matthew Nathan O'Brien Laramy, Jonathan Richard Lillis, Suman Luthra, Dafydd Rhys Owen, Klimentina Dimitrova Pencheva, Martin Youngjin Pettersson, Anil Mahadeo Rane, Matthew Forrest Sammons, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst, Jamison Bryce Tuttle, Robert Louis Hoffman
  • Micelle sequestering polymers
    Patent number: 9675636
    Abstract: A polymer composition for sequestering lipid-bile acid micelles in the gastrointestinal (GI) tract is provided. The polymer composition comprises a copolymer of a pH-sensitive monomer and one or more of positively-charged monomers. The polymer composition is able to bind micelles under various physiological conditions in the GI tract and possesses the ability to flocculate the bound micelle upon exposure to a particular pH. The flocculation of the polymer:micelle complex prevents absorption of the micelle thereby causing the polymer:micelle complex to be eliminated with the fecal matter. Thus, the polymer composition described herein may be effective in reducing cholesterol, bile acid, and/or triglyceride levels and promote weight loss.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: June 13, 2017
    Assignee: UNIVERSITY OF KANSAS
    Inventors: Cory Berkland, Jian Qian, Bradley Paul Sullivan
  • MICELLE SEQUESTERING POLYMERS
    Publication number: 20150216896
    Abstract: A polymer composition for sequestering lipid-bile acid micelles in the gastrointestinal (GI) tract is provided. The polymer composition comprises a copolymer of a pH-sensitive monomer and one or more of positively-charged monomers. The polymer composition is able to bind micelles under various physiological conditions in the GI tract and possesses the ability to flocculate the bound micelle upon exposure to a particular pH. The flocculation of the polymer:micelle complex prevents absorption of the micelle thereby causing the polymer:micelle complex to be eliminated with the fecal matter. Thus, the polymer composition described herein may be effective in reducing cholesterol, bile acid, and/or triglyceride levels and promote weight loss.
    Type: Application
    Filed: January 29, 2015
    Publication date: August 6, 2015
    Inventors: Cory Berkland, Jian Qian, Bradley Paul Sullivan